Catania

• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Belimumab CTD-ILD - Long Term Extension/Follow up to pivotal studies BLISSc-ILD and BEconneCTD-ILD Recruiting
  2023-509370-39-00 5 2025-06-03 connective tissue diseases
• Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli … Recruiting
  2024-514732-24-00 6 2025-04-28 Juvenile idiopathic arthritis
• A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal … Recruiting
  2023-507097-41-01 5 2025-03-20 Patients with limited-stage small cell lung cancer (LS-SCLC) without
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 5 2024-06-07 Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting
  2023-503545-67-00 5 2024-04-30 Tourette's Disorder
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 5 2023-11-16 Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting
  2022-501427-24-00 4 2023-04-25 Nonadvanced Systemic Mastocytosis
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting
  2023-505766-28-00 10 2022-10-10 Hereditary angioedema
• A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s … Recruiting
  2024-518223-29-00 4 2020-03-10 Advanced or metastatic untreated EGFR mutation positive NSCLC
• Study of STK-012 Alone and with Other Treatments in Patients with Advanced Lung Cancer and Other Cancers Recruiting
  2025-522632-14-00 4 2026-05-11 Non-small cell lung cancer (NSCLC)
• Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postop … Recruiting
  2025-523367-38-00 5 2026-05-11 Postoperative inflammation after cataract surgery
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus

Showing 49–72 of 395 trials